NATERA INC

Discover how Natera’s partnership with EXEL aims to expand its liquid‑biopsy portfolio into colorectal cancer diagnostics, tackle reimbursement hurdles, and outpace competitors.

Explore how Natera’s ctDNA platform powers a Phase‑3 colorectal cancer study with Exelixis, boosting oncology diagnostics and investor confidence.

Discover how Natera’s upcoming ALTAIR trial data could reshape cfDNA diagnostics, reimbursement, and healthcare workflows—and what it means for investors.

Discover how Natera’s acquisition of Foresight and Canaccord’s “Buy” rating boost precision diagnostics and investor confidence.

Explore Natera’s market dynamics, growth prospects, and risk factors—an in‑depth look at its liquid biopsy & prenatal testing strategy, competitive landscape, and future outlook.

Discover why Natera’s upgraded stock‑price target reflects its winning cfDNA platform, FDA‑cleared NIPT and oncology liquid biopsies, and future growth plans.

Natera Inc., a leading biotechnology firm, has demonstrated sustained growth in the diagnostic sector, driven by factors such as rising maternal age, public awareness, and regulatory acceptance, positioning it for continued success in the European m…

Natera Inc. is well-positioned to capitalize on the growing liquid biopsy market, driven by its stable financial profile, focused product strategy, and resilient investor sentiment.

Natera, a genetic testing company, has received a patent ruling update in its ongoing litigation with NeoGenomics, with its stock price remaining strong at $169.34 USD.

Natera Inc. is poised for significant growth in the genetic testing market due to its innovative approach, leadership position, and increasing demand for its services in cancer diagnosis and treatment.